We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $12K invested in ELITE PHARMACEUTICAL in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

20% less capital invested

Capital invested by funds: $15K → $12K (-$3K)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q2 2021 in Review

2 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2021, worth a combined $12K — down 20% from $15K a quarter earlier.

Fund positioning in ELI was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $12K of ELITE PHARMACEUTICAL stock for Q2 2021, down 20% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q2 2021 and 0 closed out.

Based on aggregated 13F filings for Q2 2021.